Bausch Health(BHC)
icon
搜索文档
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
Zacks Investment Research· 2024-02-22 02:11
Bausch Health (BHC)盈利表现 - Bausch Health (BHC)是一家属于Zacks Medical - Generic Drugs行业的公司,过去两个季度一直表现出超过盈利预期的趋势[1],[2] - 在最近一个季度,Bausch的盈利预期为每股0.92美元,实际报告为每股1.03美元,超出预期11.96%[3] - 公司的盈利预期一直在上升,部分归功于过去的盈利惊喜历史[4]
Bausch Health(BHC) - 2023 Q4 - Annual Results
2024-02-22 00:00
Exhibit 99.1 Investor Contacts: Media Contact: Solebury Strategic Communications Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2023 RESULTS • Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic1 basis • Full-Year revenues of $8.76 billion, up 8% on a Reported basis and 7% on an Organic1 basis • Full-Year revenue growth in Salix, International, ...
Bausch Health(BHC) - 2023 Q4 - Annual Report
2024-02-22 00:00
Exhibit 99.1 Investor Contacts: Media Contact: Solebury Strategic Communications Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 BAUSCH HEALTH ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2023 RESULTS • Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic1 basis • Full-Year revenues of $8.76 billion, up 8% on a Reported basis and 7% on an Organic1 basis • Full-Year revenue growth in Salix, International, ...
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
Zacks Investment Research· 2024-02-21 23:16
We are in the last leg of the fourth-quarter 2023 reporting cycle and a lot of pharma and biotech bigwigs have already reported results. The picture looks reasonably good. Bellwether J&J reported strong fourth-quarter results, wherein its earnings and sales beat their respective estimates. Swiss pharma giant Novartis’ sales and earnings lagged their respective estimates.Among the biotechs, Biogen reported lower-than-expected results for the fourth quarter, as both its earnings and sales missed estimates. Gi ...
Insights Into Bausch (BHC) Q4: Wall Street Projections for Key Metrics
Zacks Investment Research· 2024-02-19 23:21
Wall Street analysts forecast that Bausch Health (BHC) will report quarterly earnings of $1.01 per share in its upcoming release, pointing to a year-over-year decline of 1%. It is anticipated that revenues will amount to $2.25 billion, exhibiting an increase of 2.4% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 1.3% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial es ...
Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research· 2024-02-16 00:06
Wall Street expects a year-over-year decline in earnings on higher revenues when Bausch Health (BHC) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 22, 2024, might help the stock move higher if these key numbers are better than ...
Bausch (BHC) Upgraded to Strong Buy: What Does It Mean for the Stock?
Zacks Investment Research· 2024-02-08 02:01
Bausch Health (BHC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the syst ...
Best Value Stocks to Buy for February 7th
Zacks Investment Research· 2024-02-07 17:06
Mitsui & Co., Ltd. (MITSY) - Mitsui & Co., Ltd.是一家投资和贸易公司,拥有Zacks Rank 1,近60天内其当前年度盈利的Zacks Consensus Estimate增长了4.8% [1] - Mitsui & Co., Ltd.的市盈率(P/E)为8.84,行业平均为21.60,公司的价值评分为A [2] J Sainsbury plc (JSAIY) - J Sainsbury plc是一家多元化的零售和金融服务公司,拥有Zacks Rank 1,近60天内其当前年度盈利的Zacks Consensus Estimate增长了2% [3] - J Sainsbury plc的市盈率(P/E)为13.72,行业平均为14.00,公司的价值评分为A [4] Bausch Health Companies Inc. (BHC) - Bausch Health Companies Inc.是一家制药公司,拥有Zacks Rank 1,近60天内其明年盈利的Zacks Consensus Estimate增长了2.9% [5] - Bausch Health Companies的市盈率(P/E)为2.00,标普500指数为21.97,公司的价值评分为A [6]
Bausch Health(BHC) - 2023 Q3 - Earnings Call Transcript
2023-11-02 22:12
财务数据和关键指标变化 - 第三季度Bausch Health(不含Bausch & Lomb)的收入为12.3亿美元,同比增长12%,有机增长10% [29] - Salix收入增长13%,主要由于Xifaxan、Relistor和Trulance的增长 [30][31] - 国际收入增长10%,主要由于拉丁美洲和波兰的强劲表现 [32] - Solta Medical收入增长15%,主要由于亚太地区(包括中国)的强劲需求 [32] - 多元化收入增长9%,主要由于神经系统和仿制药业务的增长 [34] - 牙科收入小幅下降4% [19] - 毛利率为81.3%,同比增加50个基点 [38] - 调整后EBITDA为6.64亿美元,同比增长约10% [42] 各条业务线数据和关键指标变化 - Salix业务: - Xifaxan收入增长13%,但实际需求增长仅1% [30][31] - Relistor和Trulance收入分别增长28%和10% [31] - 国际业务: - 收入增长4%,主要由于拉丁美洲和波兰的强劲表现 [32] - Solta Medical业务: - 收入增长17%,主要由于亚太地区(包括中国)的强劲需求 [32] - 70%以上收入来自耗材销售,业务前景良好 [17] - 多元化业务: - 神经系统和仿制药业务受益于竞争对手供应中断,实现增长 [34] - 但神经系统和皮肤科业务长期面临挑战 [35][36] - 牙科业务在前两个季度增长良好,第三季度小幅下降4% [19] 各个市场数据和关键指标变化 - 美国市场: - Solta Medical业务实现低个位数增长 [16] - 亚太地区: - Solta Medical业务增长强劲 [16][32] - 拉丁美洲: - 国际业务增长强劲 [32] - 波兰: - 国际业务增长强劲 [32] 公司战略和发展方向及行业竞争 - 公司继续专注于商业卓越、加强业务开发和推进管线 [27][63] - 正在评估Bausch & Lomb的潜在完全分拆,但目前仍在专注于管理资产负债表 [12][21] - 正在积极推进Xifaxan的知识产权保护,并取得了一些胜利性进展 [10][11] - 推出了针对肝性脑病的营销活动,以提高患者和医生的认知度 [15] - 在皮肤科领域获得了CABTREO的FDA批准,这是一款针对青春痘的创新产品 [24][25] - Solta Medical业务正在加大营销和销售团队投入,以加速增长 [17] 管理层对经营环境和未来前景的评论 - 管理层对Salix、国际和Solta Medical业务的未来前景持乐观态度 [14][16][17] - 但对神经系统和皮肤科业务的长期挑战表示担忧 [35][36] - 预计Salix业务全年增长将达到中高个位数 [52] - 国际业务全年增长预计与前三个季度保持一致 [53] - Solta Medical业务预计将继续保持强劲的报告和有机增长 [53] - 多元化业务全年销售预计将下降,主要受神经系统和皮肤科业务的拖累 [55] 问答环节重要的提问和回答 问题1 **Jason Gerberry 提问** 询问新任CFO的聘任进度以及Bausch & Lomb分拆的具体选项 [67] **Thomas Appio 和 John Barresi 回答** - 新CFO的聘任正在进行中,目前由John Barresi担任临时CFO [68][69] - 分拆Bausch & Lomb的具体选项包括通过减资方式进行,这样可以简化流程并提高灵活性 [69][70] 问题2 **Umer Raffat 提问** 询问Xifaxan专利诉讼的最新进展以及Amiselimod的心脏安全性 [80] **Thomas Appio 回答** - Xifaxan专利诉讼的地区法院裁决正在上诉,预计2024年第一季度会有结果 [83] - Amiselimod的心脏安全性研究已经完成,结果是积极的 [84] 问题3 **Douglas Miehm 提问** 询问Xifaxan和Aplenzin/Wellbutrin销售增长的原因 [92] **Thomas Appio 和 John Barresi 回答** - Xifaxan销售增长一部分来自价格上涨,一部分来自渠道库存变化,实际需求增长有限 [93][94] - Aplenzin和Wellbutrin销售增长主要受益于竞争对手供应中断,但预计第四季度会有所下降 [95][96]
Bausch Health(BHC) - 2023 Q3 - Earnings Call Presentation
2023-11-02 19:40
Q3 2023 Earnings November 2, 2023 BAUSCH Health Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements relating to Bausch Health Companies Inc.'s ("Bausch Health" or the "Company") future prospects and performance, financial guidance, research and development efforts and anticipated timing thereof, proposed plan to separate its ey ...